Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.39 AUD | +0.13% | +0.07% | +52.68% |
05:34am | Telix Pharmaceuticals Concludes Proof-of-Concept Study of Advanced Prostate Cancer Drug | MT |
May. 20 | Telix Pharmaceuticals Files Registration Statement for Nasdaq IPO | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+52.68% | 3.43B | |
+42.29% | 54.04B | |
+43.57% | 41.96B | |
-1.39% | 41.92B | |
-7.59% | 28.35B | |
+11.63% | 26.35B | |
-22.24% | 19B | |
+7.83% | 13B | |
+28.42% | 12.28B | |
+25.69% | 12.19B |
- Stock Market
- Equities
- TLX Stock
- News Telix Pharmaceuticals Limited
- Telix Pharmaceuticals to Acquire QSAM Biosciences and Its Bone Cancer Targeting Platform